These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes. Lehmann DF; Lohray BB J Clin Pharmacol; 2008 Aug; 48(8):999-1002. PubMed ID: 18650500 [No Abstract] [Full Text] [Related]
10. [The PPARgamma receptor agonists and prevention of cardio-vascular complications in patients with type 2 diabetes. The results of the PROactive study]. Szymborska-Kajanek A; Strojek K Kardiol Pol; 2006 Mar; 64(3):322-5; discussion 325-6. PubMed ID: 16583340 [No Abstract] [Full Text] [Related]
11. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Blaschke F; Caglayan E; Hsueh WA Endocrinol Metab Clin North Am; 2006 Sep; 35(3):561-74, ix. PubMed ID: 16959586 [TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Decker M; Hofflich H; Elias AN Diabetes Obes Metab; 2008 Aug; 10(8):617-25. PubMed ID: 17645549 [TBL] [Abstract][Full Text] [Related]
13. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
14. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs? Buckingham RE; Hanna A Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890 [TBL] [Abstract][Full Text] [Related]
15. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention. Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887 [TBL] [Abstract][Full Text] [Related]
16. PPARgamma agonists, modulation of ion transporters, and fluid retention. Nofziger C; Blazer-Yost BL J Am Soc Nephrol; 2009 Dec; 20(12):2481-3. PubMed ID: 19820124 [No Abstract] [Full Text] [Related]
17. Can PPARgamma agonists have a role in the management of obesity-related hypertension? Chetty VT; Sharma AM Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364 [TBL] [Abstract][Full Text] [Related]
18. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Khanderia U; Pop-Busui R; Eagle KA Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014 [TBL] [Abstract][Full Text] [Related]
19. Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential. Yang J; Zhang D; Li J; Zhang X; Fan F; Guan Y Clin Sci (Lond); 2009 Jan; 116(1):17-26. PubMed ID: 19037881 [TBL] [Abstract][Full Text] [Related]